Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2016

Open Access 01-12-2016 | Research article

Predictors of time to relapse in amphetamine-type substance users in the matrix treatment program in Iran: a Cox proportional hazard model application

Authors: Maryam Moeeni, Emran M. Razaghi, Koen Ponnet, Fatemeh Torabi, Seyed Ali Shafiee, Tahereh Pashaei

Published in: BMC Psychiatry | Issue 1/2016

Login to get access

Abstract

Background

The aim of this study was to determine which predictors influence the risk of relapse among a cohort of amphetamine-type substance (ATS) users in Iran.

Methods

A Cox proportional hazards model was conducted to determine factors associated with the relapse time in the Matrix treatment program provided by the Iranian National Center of Addiction Studies (INCAS) between March 2010 and October 2011.

Results

Participating in more treatment sessions was associated with a lower probability of relapse. On the other hand, patients with less family support, longer dependence on ATS, and those with an experience of casual sex and a history of criminal offenses were more likely to relapse.

Conclusion

This study broadens our understanding of factors influencing the risk of relapse in ATS use among an Iranian sample. The findings can guide practitioners during the treatment program.
Literature
1.
UNODC. Global ATS Assessment: Amphetamines and Ecstasy. Vienna: United Nations; 2008.
2.
3.
Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010;105(6):991–1002.CrossRefPubMed
4.
Lashkaripour K, Torbati E. Methamphetamine dependency. International Journal of High Risk Behaviors and Addiction. 2012;1(1):7–8.CrossRef
5.
Shariatirad S, Maarefvand M, Ekhtiari H. Emergence of a methamphetamine crisis in Iran. Drug and alcohol review. 2013;32(2):223–4.CrossRefPubMed
6.
Karrari P, Mehrpour O, Balali-Mood M. Iranian crystal: a misunderstanding of the crystal-meth. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2012;17(2):203.
7.
8.
Alizadeh N, Mohammadi A, Tabrizchi M. Rapid screening of methamphetamines in human serum by headspace solid-phase microextraction using a dodecylsulfate-doped polypyrrole film coupled to ion mobility spectrometry. Journal of Chromatography a. 2008;1183(1):21–8.CrossRefPubMed
9.
Hajiabdolbaghi M, et al. Insights from a survey of sexual behavior among a group of at-risk women in Tehran, Iran, 2006. AIDS Education & Prevention. 2007;19(6):519–30.CrossRef
10.
Otero C, et al. Methamphetamine addiction, treatment, and outcomes: Implications for child welfare workers, Publications of the Center on Children, Families, and the Law (and related organizations). 2006. p. 15.
11.
Rahimi-Movaghar A, et al. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010;14(1):e28–33.CrossRefPubMed
12.
Rawson RA, et al. An intensive outpatient approach for cocaine abuse treatment: the matrix model. J Subst Abus Treat. 1995;12(2):117–27.CrossRef
13.
Rawson RA, et al. A multi‐site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99(6):708–17.CrossRefPubMed
14.
Brecht M-L, Anglin MD, Dylan M. Coerced treatment for methamphetamine abuse: differential patient characteristics and outcomes. The American journal of drug and alcohol abuse. 2005;31(2):337–56.CrossRefPubMed
15.
Brecht M-L, et al. Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug Alcohol Depend. 2008;96(3):193–201.CrossRefPubMedPubMedCentral
16.
17.
Roll JM, et al. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatr. 2006;163(11):1993–9.CrossRefPubMed
18.
Brecht M-L, Herbeck D. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend. 2014;139:18–25.CrossRefPubMedPubMedCentral
19.
Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology. 2001;158(4):343–59.CrossRefPubMed
20.
Brecht M-L, von Mayrhauser C, Anglin MD. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs. 2000;32(2):211–20.CrossRefPubMed
21.
Shirinbayan P, et al. Predictors of retention in methadone maintenance therapy: a prospective multi-center study. Sci Res Essay. 2010;5(21):3231–6.
22.
Brecht M-L, et al. Two-year outcomes of treatment for methamphetamine use. J Psychoactive Drugs. 2006;38(sup3):415–26.CrossRef
23.
Deck D, Carlson MJ. Retention in publicly funded methadone maintenance treatment in two western states. The journal of behavioral health services & research. 2005;32(1):43–60.CrossRef
24.
Pashaei T, et al. Predictors of treatment retention in a major methadone maintenance treatment program in Iran: a survival analysis. Journal of research in health sciences. 2014;14(4):291–5.PubMed
25.
Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend. 1999;57(2):113–25.CrossRefPubMed
26.
Termorshuizen F, et al. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005;79(2):231–40.CrossRefPubMed
27.
Pashaei T, et al. Effectiveness of relapse prevention cognitive-behavioral model in opioid-dependent patients participating in the methadone maintenance treatment in Iran. Iranian Journal of Public Health. 2013;42(8):896–902.PubMedPubMedCentral
28.
Kobayashi O, et al. Profiles associated with treatment retention in Japanese patients with methamphetamine use disorder: preliminary survey. Psychiatry Clin Neurosci. 2008;62(5):526–32.CrossRefPubMed
29.
Sarasvita R, et al. Predictive factors for treatment retention in methadone programs in Indonesia. J Subst Abus Treat. 2012;42(3):239–46.CrossRef
30.
Hser Y-I, et al. Longitudinal patterns of treatment utilization and outcomes among methamphetamine abusers: a growth curve modeling approach. J Drug Issues. 2003;33(4):921–38.CrossRef
31.
Hillhouse MP, et al. Predicting in‐treatment performance and post‐treatment outcomes in methamphetamine users. Addiction. 2007;102(s1):84–95.CrossRefPubMed
32.
Rawson RA, et al. Methamphetamine dependence: a closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment. Am J Addict. 2007;16(4):291–9.CrossRefPubMed
33.
Rivkin SG, Hanushek EA, Kain JF. Teachers, schools, and academic achievement. Econometrica. 2005;73(2):417–58.CrossRef
34.
Prendergast ML, et al. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend. 2002;67(1):53–72.CrossRefPubMed
35.
Kleinbaum D, Klein M. Survival Analysis: A Self-Learning Text. New York: Springer-Verlag; 2005.
36.
Greenwood GL, et al. Relapse outcomes in a randomized trial of residential and day drug abuse treatment. J Subst Abus Treat. 2001;20(1):15–23.CrossRef
37.
Stevens SJ, et al. Ethnic and cultural differences in drug-using women who are in and out of treatment. Drugs & Society. 1998;13(1–2):81–95.CrossRef
38.
Dean AC, et al. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend. 2009;105(1):48–55.CrossRefPubMedPubMedCentral
39.
40.
Albertsen K, Borg V, Oldenburg B. A systematic review of the impact of work environment on smoking cessation, relapse and amount smoked. Prev Med. 2006;43(4):291–305.CrossRefPubMed
41.
Kaskutas LA, Bond J, Humphreys K. Social networks as mediators of the effect of alcoholics anonymous. Addiction. 2002;97(7):891–900.CrossRefPubMed
42.
Salmon MM, et al. Women's perception of provider, social, and program support in an outpatient drug treatment program. J Subst Abus Treat. 2000;19(3):239–46.CrossRef
43.
Reiber C, et al. Predicting treatment success at multiple timepoints in diverse patient populations of cocaine-dependent individuals. Drug Alcohol Depend. 2002;68(1):35–48.CrossRefPubMed
44.
Carroll KM, et al. One-year follow-up status of treatment-seeking cocaine abusers: psychopathology and dependence severity as predictors of outcome. J Nerv Ment Dis. 1993;181(2):71–9.CrossRefPubMed
45.
McMahon RC. Personality, stress, and social support in cocaine relapse prediction. J Subst Abus Treat. 2001;21(2):77–87.CrossRef
46.
Tavakoli M, et al. Status and trend of substance abuse and dependence among Iranian women. Journal of Rehabilitation. 2014;14(5):30–7.
47.
Khajedaluee M, Moghadam MD. Methods and patterns of drug abuse among young addict women. Journal of Research & Health. 2013;3(4):527–35.
48.
Metadata
Title
Predictors of time to relapse in amphetamine-type substance users in the matrix treatment program in Iran: a Cox proportional hazard model application
Authors
Maryam Moeeni
Emran M. Razaghi
Koen Ponnet
Fatemeh Torabi
Seyed Ali Shafiee
Tahereh Pashaei
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2016
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-016-0973-8

Other articles of this Issue 1/2016

BMC Psychiatry 1/2016 Go to the issue

Research article

A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia

Research article

A history of childhood trauma is associated with slower improvement rates: Findings from a one-year follow-up study of patients with a first-episode psychosis

Study protocol

Effects of delaying binge drinking on adolescent brain development: a longitudinal neuroimaging study

Research article

Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study

Study protocol

A randomized controlled study of exposure therapy as aftercare for alcohol use disorder: study protocol

Study protocol

The efficacy of behavioural activation treatment for co-occurring depression and substance use disorder (the activate study): a randomized controlled trial